Current UK Guidelines for Management of Phyllodes Tumours of the Breast

Overview

Phyllodes tumours (PT) are rare biphasic breast tumours classified as benign, borderline, or malignant, guiding prognosis and treatment. UK guidelines emphasize multidisciplinary management, accurate diagnosis, and tailored surgical approaches to optimize outcomes and reduce overtreatment.

Background

Phyllodes tumours account for approximately 0.5% of breast tumours, predominantly affecting women in their 40s and 50s. They are classified into benign, borderline, and malignant categories, with varying recurrence risks. Management practices vary internationally and within the UK, with specialist centres demonstrating improved diagnostic and treatment outcomes. Existing guidelines are often embedded within broader sarcoma or breast cancer protocols, prompting the need for dedicated, accessible recommendations.

Data Highlights

Incidence of malignant phyllodes tumours in England is approximately 60 new cases per year, equating to 2 per 1,000,000 women. Distribution of PT subtypes is: benign (50–70%), borderline (12–26%), and malignant (20–30%). A series of 83 growing fibroadenomas showed a 2.4% incidence of subsequent PT diagnosis. Growth >15% in volume per month in fibroadenomas may indicate suspicion for PT.

Key Findings

• Phyllodes tumours are biphasic neoplasms with stromal and epithelial components, requiring histological classification into benign, borderline, or malignant for management decisions.
• Clinical suspicion should be raised for lesions >4 cm, lobulated or multinodular on imaging, or enlarging fibroadenomas, especially with prior excision history.
• Preoperative biopsy and management at specialist sarcoma centres reduce the need for multiple surgeries and improve diagnostic accuracy.
• Distinguishing PT from cellular fibroadenomas relies on stromal cellularity assessment, which can be challenging pathologically.
• Genetic syndromes such as Li–Fraumeni (TP53 mutation) may be associated with PT, though other germline mutations have unclear links.
• Multidisciplinary team involvement and consensus guidelines aim to standardize care and reduce overtreatment, particularly of benign lesions.

Clinical Implications

Clinicians should maintain a high index of suspicion for PT in patients presenting with enlarging breast lumps, especially those with prior fibroadenoma excision or large lesions on imaging. Referral to specialist centres with sarcoma expertise is recommended to optimize biopsy accuracy and surgical planning. Multidisciplinary collaboration and adherence to these guidelines can streamline care and minimize unnecessary interventions.

Conclusion

These UK guidelines provide evidence-based, consensus-driven recommendations to improve the diagnosis and management of phyllodes tumours, promoting best practices and reducing variability in care. Adoption of these standards is expected to enhance patient outcomes and resource utilization.

References

1. UK Association of Breast Surgery Guidelines 2024 -- Current Approaches to the Management of Phyllodes Tumours in the Breast